Proprietary mutations for reduced Fc-effector functions.
CrossPoint’s Stealth-Body shows no binding or activity above background across Fc gamma receptors, far surpassing all previously described modifications.
CrossPoint’s Stealth-Body limits off-target toxicity issues for the development of next-generation antibody therapies.
MISSION
Key to the success of
novel drug development
CrossPoint Therapeutics strives to develop drugs that